Ranbaxy Loses Its Exclusivity For Stomach Treatment Drug
Advertisement
Advertisement
Advertisement
In a letter to the National Stock Exchange (“We have now received a communication from the USFDA that they have determined that Ranbaxy has forfeited its 180 day exclusivity for esomeprazole magnesium delayed release capsule 20 mg and 40 mg,” the company said in its disclosure to the exchange.
It further added, “On November 4, 2014, we received a notice from the USFDA rescinding our tentative approvals for Esomeprazole magnesium delayed release capsule 20 mg and 40 mg and for valganciclovir hydrochloride tablets USP, 450mg.”
The company has expressed its disappointment over the latest development and is considering legal recourse to preserve its rights on the drugs.
Representational Image
Advertisement
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- A centenarian who starts her day with gentle exercise and loves walks shares 5 longevity tips, including staying single
- 2 states where home prices are falling because there are too many houses and not enough buyers
- 7 Nutritious and flavourful tiffin ideas to pack for school
- India's e-commerce market set to skyrocket as the country's digital economy surges to USD 1 Trillion by 2030
- Top 5 places to visit near Rishikesh
- Indian economy remains in bright spot: Ministry of Finance
- A surprise visit: Tesla CEO Elon Musk heads to China after deferring India visit
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market